Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyDiseaseNHL, T-cell typeSubgroupICD10C84.5MeSHCentral Nervous System NeoplasmsSequenceChemotherapyChemo-substanceIfosfamideMethotrexateChemo-substanceIfosfamideMethotrexateChemo-substanceIfosfamideMethotrexateChemo-substanceIfosfamideMethotrexateNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%FilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%Potassium chlorideSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%FilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%Potassium chlorideSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%FilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%Potassium chlorideSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%FilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%Potassium chlorideSodium BicarbonateNo. Substances11Protocol classificationTherapy classificationcurrent standardIntensityhigh doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlEmetogenicityFebrile NeutropeniaNephrotoxicityNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorFischer LDiseasePrimäres ZNS-LymphomOriginDepartment of Hematology, Oncology and Transfusion Medicine, Charité Universitätsmedizin BerlinProtocols in Revision 1 protocol foundMethotrexate 4000 / Ifosfamide 1.5, primary lymphoma of the central nervous system (PID3217 V1.0)
